UCB

UCB is a global biopharmaceutical company that researches, develops, and delivers medicines and patient solutions for people living with severe neurological and autoimmune diseases. Founded in 1928 and headquartered in Brussels, Belgium, the company employs more than 10,000 people and operates in nearly 40 countries. Revenue for 2025 was €7.7 billion, and more than 3.1 million patients access UCB solutions.

Its work concentrates on neurology and immunology, spanning biopharmaceutical research and development, drug discovery and development, and patient-centered scientific innovation. Areas of focus include epilepsy, myasthenia gravis, psoriasis, hidradenitis suppurativa and osteoporosis, with an emphasis on unmet medical needs and differentiated treatments.

UCB combines scientific innovation with insights drawn from patients and caregivers, and supports people throughout their care journey. The company works with healthcare professionals, academic institutions, biotechnology companies and other partners, operating across a global footprint of nearly 40 countries.